spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  soft tissue infection 

 HSMN NewsFeed - 18 Jan 2022
Dermaliq Therapeutics Signs USD 15 Million Series A Round to Advance Three Transformative Drug Therapies into Clinical Trials
Biopharmaceuticals Dermatology Venture Capital
 HSMN NewsFeed - 10 Dec 2020
Wound Care Plus, LLC Adopts the MolecuLight i:X(R) as a Standard Point-of-Care Device for its Wound Care Service Offering to the Long-Term Care and Extended Care Markets
Devices Wound Care
 HSMN NewsFeed - 31 May 2016
Allergan Receives FDA Approval of TEFLARO(R) (ceftaroline fosamil) for Pediatric Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Feb 2016
FDA Accepts Supplemental New Drug Application (sNDA) for TEFLARO(R) (ceftaroline fosamil)
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Jan 2016
Allergan Announces FDA Approval of Updated Label for New Dosing Regimen for DALVANCE(R) (dalbavancin)
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Jan 2015
The Medicines Company Receives CHMP Positive Opinions for Three Hospital Acute Care Products: KENGREXAL(TM) (cangrelor), ORBACTIV(TM) (oritavancin) and RAPLIXA(TM) (sealant powder)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Jul 2014
Durata Therapeutics Announces the U.S. Launch of DALVANCE(TM)
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 25 Feb 2013
Industry Veteran Carolyn Twomey Joins IrriMax(R) Corporation as Vice President, Clinical Affairs
Devices Wound Care Personnel
 HSMN NewsFeed - 15 Sep 2011
Astellas and Theravance Announce European Marketing Authorization for VIBATIV(R) for Nosocomial Pneumonia Caused by MRSA
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Apr 2011
Durata Therapeutics Initiates Phase 3 Study of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Biopharmaceuticals
 HSMN NewsFeed - 13 Jan 2010
Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Ofloxacin and Fleroxacin
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Feb 2009
Basilea Pharmaceutica files claims against Johnson&Johnson over its handling of ceftobiprole (ZEFTERA(TM)/Zevtera(TM)) clinical studies
Biopharmaceuticals Litigation
 HSMN NewsFeed - 24 Feb 2009
CHMP delays European Commission decision process to approve ZEVTERA(TM)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Jan 2009
Environmental Tectonics Corporation Announces the Sale of Two BARA-MED(R) XD Monoplace Hyperbaric Chambers
Devices
 HSMN NewsFeed - 26 Nov 2008
FDA Issues Complete Response Letter for Ceftobiprole for Treatment of Complicated Skin Infections
Biopharmaceuticals
 HSMN NewsFeed - 21 Nov 2008
Zevtera(TM) (ceftobiprole medocaril), the novel anti-MRSA broad-spectrum antibiotic, receives a positive opinion from the CHMP
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 29 Sep 2008
Cepheid Receives FDA Clearance for First Rapid On-Demand Molecular Diagnostic Test for MRSA and S. aureus
Diagnostics FDA
 HSMN NewsFeed - 28 Jul 2008
Arpida Submits Marketing Authorisation Application for Intravenous Iclaprim in Europe
Biopharmaceuticals
 HSMN NewsFeed - 22 Jul 2008
Nosocomial Vaccines - Minefield or Goldmine?
Biopharmaceuticals
 HSMN NewsFeed - 30 Jun 2008
Ceftobiprole, a new anti-MRSA broad-spectrum antibiotic, receives its first marketing authorization by Health Canada
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 17 Mar 2008
GE Healthcare Grows #1 Market Leadership Position in Global Compact Ultrasound Industry in 2007
Devices
 HSMN NewsFeed - 4 Dec 2007
Cepheid Launches New GeneXpert(R) Tests in Europe for Simultaneous, Rapid Detection of Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus
Diagnostics
 HSMN NewsFeed - 12 Sep 2007
New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
Biopharmaceuticals
 HSMN NewsFeed - 18 Jun 2007
Basilea Announces Submission of Marketing Authorization Application in Europe by Janssen-Cilag International NV for Ceftobiprole, a Novel Anti-MRSA Broad-spectrum Cephalosporin
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 May 2007
Theravance Announces Acceptance of Telavancin MAA for the Treatment of Complicated Skin and Soft Tissue Infections in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 1 May 2007
Astellas and Theravance Announce Submission of Telavancin MAA for the Treatment of Complicated Skin and Soft Tissue Infections in Europe
Biopharmaceuticals Regulatory
Return to NewsFeed  

 Additional items found! 12

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 12 additional stories matching:
soft tissue infection
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!